Monteris commercially releases NB3 FullFire probe
Monteris Medical commercially released the NeuroBlate NB3 FullFire 1.6 mm laser probe for use with its robotic MRI-guided laser ablation system.
Evidence notes
- The company described NB3 FullFire as the smallest commercially available laser probe for use in the brain.
- FDA 510(k) clearance was secured in December 2023 before the 2024 market release.
- The probe is part of the NeuroBlate robotic MRI-guided laser ablation system.
Company context
Develops minimally invasive neurosurgery systems centered on the NeuroBlate platform for MRI-guided laser interstitial thermal therapy in the brain. The company combines robotic control, cooled laser probe technology, software, and treatment-planning workflow to support targeted ablation of brain lesions in adult and pediatric patients.